Trends in burden of multidrug-resistant tuberculosis in countries, regions, and worldwide from 1990 to 2017: results from the Global Burden of Disease study

Abstract

Background Antituberculosis-drug resistance is an important public health issue, and its epidemiological patterns has dramatically changed in recent decades. This study aimed to estimate the trends of multidrug-resistant tuberculosis (MDR-TB), which can be used to inform health strategies. Methods Data were collected from the Global Burden of Disease study 2017. The estimated annual percentage changes (EAPCs) were calculated to assess the trends of MDR-TB burden at global, regional, and national level from 1990 to 2017 using the linear regression model. Results Globally, the age-standardized rate (ASR) of MDR-TB burden including incidence, prevalence, death and disability-adjusted life years (DALYs) had pronounced increasing trends from 1990 to 1999, with the EAPCs were 17.63 [95% confidence interval (CI): 10.77–24.92], 17.57 (95% CI 11.51–23.95), 21.21 (95% CI 15.96–26.69), and 21.90 (95% CI 16.55–27.50), respectively. Particularly, the largest increasing trends were seen in areas and countries with low and low-middle sociodemographic index (SDI). However, the trends in incidence, prevalence, death and DALYs of MDR-TB decreased globally from 2000 to 2017, with the respective EAPCs were − 1.37 (95% CI − 1.62 to − 1.12), − 1.32 (95% CI − 1.38 to − 1.26), − 3.30 (95% CI − 3.56 to − 3.04) and − 3.32 (95% CI − 3.59 to − 3.06). Decreasing trends of MDR-TB were observed in most regions and countries, particularly that of death and DALYs in Slovenia were − 18.96 (95% CI − 20.82 to − 17.06) and -19.35 (95% CI − 21.10 to − 17.55), respectively. Whereas the pronounced increasing trends of MDR-TB occurred in Papua New Guinea, Singapore, and Australia. Conclusions The ASR of MDR-TB showed pronounced decreasing trends from 2000 to 2017. However, the MDR-TB burden remains a substantial challenge to the TB control globally, and requires effective control strategies and healthcare systems.

ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination Against COVID-19 in Individuals at Risk

“…A second BCG vaccination may act as a booster for trained immunity particularly since BCG protection is waning for people who were vaccinated before the age of 5 years ( 38 , 39 ). From a similar point of view, results of the Global Burden of Disease Study report that the incidence of tuberculosis is steadily changing from 1990 to 2017; this decreased in China ( 40 ), Eastern Asia, Central Asia, Western Europe, North America, and Southern Latin America but increased in Southern Asia, Oceania, Eastern Europe, and Central Latin America ( 41 , 42 ) whatever may have a major impact on the trained immunity of populations by M. tuberculosis.…”

Global trends in incidence and death of neonatal disorders and its specific causes in 204 countries/territories during 1990–2019

“…Estimated annual percentage change (EAPC) is a well-accepted method of quantifying the trends of ASR, which have been wildly used in public health studies [ 20 , 21 ]. A regression line was fitted to the natural logarithm of the rates.…”

Epidemic Trends in High Tuberculosis Burden Countries During the Last Three Decades and Feasibility of Achieving the Global Targets at the Country Level

“…The programmatic management of latent tuberculosis infection (LTBI) is one of the crucial interventions to decrease the incidence ( 25 ). In addition, addressing the MDR-TB epidemic is crucial to reducing morbidity, mortality, and healthcare related costs ( 26 , 27 ). The long-term socio-economic effects will further drive risk factors associated with TB, such as poverty, malnutrition, and poor living conditions ( 24 ).…”